Listed

Globus Medical Inc

GMEDNYSECIK 1237831HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$789.6mRevenue, Q2 FY2026, three months to 2026-06-30$789.6m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001628280-26-054450.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 6, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$789.6mRevenue, Q2 FY2026, three months to 2026-06-30$789.6m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001628280-26-054450.Report this figure+5.9% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin23.1%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $182.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-054450.Revenue: $789.6m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001628280-26-054450.Report this figure+12.9 pts on a year earlier
  • Net margin19.2%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $151.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-054450.Revenue: $789.6m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001628280-26-054450.Report this figure−8.0 pts on a year earlier
  • Diluted EPS$1.10Diluted EPS, Q2 FY2026, three months to 2026-06-30$1.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001628280-26-054450.Report this figure−26.2% on a year earlier
  • Free cash flow$176.6mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $209.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001628280-26-054450. Derived: 6-month figure less the 3-month figure.Capital expenditure: $33.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001628280-26-054450. Derived: 6-month figure less the 3-month figure.Report this figure+464.1% on a year earlier

Last eight quarters

Full statements
Revenue$789.6mOperating margin 23.1%
Diluted EPS$1.10, Q2 FY2026
Free cash flow$176.6m, Q2 FY2026
Globus Medical Inc, key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m626Revenue, Q3 FY2024, three months to 2024-09-30$625.7m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-06, accession 0001237831-25-000031.Report this figure657Revenue, Q4 FY2024, three months to 2024-12-31$657.3m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-24, accession 0001628280-26-011209. Derived: 12-month figure less the 9-month figure.Report this figure598Revenue, Q1 FY2025, three months to 2025-03-31$598.1m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-07, accession 0001628280-26-032290.Report this figure745Revenue, Q2 FY2025, three months to 2025-06-30$745.3m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001628280-26-054450.Report this figure769Revenue, Q3 FY2025, three months to 2025-09-30$769.0m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-06, accession 0001237831-25-000031.Report this figure826Revenue, Q4 FY2025, three months to 2025-12-31$826.4m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-24, accession 0001628280-26-011209. Derived: 12-month figure less the 9-month figure.Report this figure760Revenue, Q1 FY2026, three months to 2026-03-31$759.9m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-07, accession 0001628280-26-032290.Report this figure790Revenue, Q2 FY2026, three months to 2026-06-30$789.6m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001628280-26-054450.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%7.7%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $48.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001237831-25-000031.Revenue: $625.7m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-06, accession 0001237831-25-000031.Report this figure9.2%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $60.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0001628280-26-011209. Derived: 12-month figure less the 9-month figure.Revenue: $657.3m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-24, accession 0001628280-26-011209. Derived: 12-month figure less the 9-month figure.Report this figure16.2%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $97.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001628280-26-032290.Revenue: $598.1m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-07, accession 0001628280-26-032290.Report this figure10.2%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $76.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-054450.Revenue: $745.3m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001628280-26-054450.Report this figure17.9%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $137.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001237831-25-000031.Revenue: $769.0m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-06, accession 0001237831-25-000031.Report this figure20.5%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $169.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0001628280-26-011209. Derived: 12-month figure less the 9-month figure.Revenue: $826.4m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-24, accession 0001628280-26-011209. Derived: 12-month figure less the 9-month figure.Report this figure19.8%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $150.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001628280-26-032290.Revenue: $759.9m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-07, accession 0001628280-26-032290.Report this figure23.1%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $182.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-054450.Revenue: $789.6m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001628280-26-054450.Report this figure
Net margin%8.3%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $51.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001237831-25-000031.Revenue: $625.7m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-06, accession 0001237831-25-000031.Report this figure4.0%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $26.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0001628280-26-011209. Derived: 12-month figure less the 9-month figure.Revenue: $657.3m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-24, accession 0001628280-26-011209. Derived: 12-month figure less the 9-month figure.Report this figure12.6%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $75.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001628280-26-032290.Revenue: $598.1m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-07, accession 0001628280-26-032290.Report this figure27.2%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $202.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-054450.Revenue: $745.3m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001628280-26-054450.Report this figure15.5%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $119.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001237831-25-000031.Revenue: $769.0m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-06, accession 0001237831-25-000031.Report this figure17.0%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $140.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0001628280-26-011209. Derived: 12-month figure less the 9-month figure.Revenue: $826.4m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-24, accession 0001628280-26-011209. Derived: 12-month figure less the 9-month figure.Report this figure16.4%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $124.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001628280-26-032290.Revenue: $759.9m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-07, accession 0001628280-26-032290.Report this figure19.2%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $151.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-054450.Revenue: $789.6m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001628280-26-054450.Report this figure
Diluted EPS$ per share0.38Diluted EPS, Q3 FY2024, three months to 2024-09-30$0.38 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001237831-25-000031.Report this figurenot reported (Diluted EPS not reported)0.54Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.54 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001628280-26-032290.Report this figure1.49Diluted EPS, Q2 FY2025, three months to 2025-06-30$1.49 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001628280-26-054450.Report this figure0.88Diluted EPS, Q3 FY2025, three months to 2025-09-30$0.88 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001237831-25-000031.Report this figurenot reported (Diluted EPS not reported)0.90Diluted EPS, Q1 FY2026, three months to 2026-03-31$0.90 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001628280-26-032290.Report this figure1.10Diluted EPS, Q2 FY2026, three months to 2026-06-30$1.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001628280-26-054450.Report this figure
Free cash flow$m162Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $203.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001237831-25-000031. Derived: 9-month figure less the 6-month figure.Capital expenditure: $42.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001237831-25-000031. Derived: 9-month figure less the 6-month figure.Report this figure193Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $210.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-24, accession 0001628280-26-011209. Derived: 12-month figure less the 9-month figure.Capital expenditure: $17.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-24, accession 0001628280-26-011209. Derived: 12-month figure less the 9-month figure.Report this figure141Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $177.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001628280-26-032290.Capital expenditure: $36.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001628280-26-032290.Report this figure31.3Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $77.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001628280-26-054450. Derived: 6-month figure less the 3-month figure.Capital expenditure: $46.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001628280-26-054450. Derived: 6-month figure less the 3-month figure.Report this figure214Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $249.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001237831-25-000031. Derived: 9-month figure less the 6-month figure.Capital expenditure: $35.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001237831-25-000031. Derived: 9-month figure less the 6-month figure.Report this figure202Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $248.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-24, accession 0001628280-26-011209. Derived: 12-month figure less the 9-month figure.Capital expenditure: $46.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-24, accession 0001628280-26-011209. Derived: 12-month figure less the 9-month figure.Report this figure163Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $202.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001628280-26-032290.Capital expenditure: $39.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001628280-26-032290.Report this figure177Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $209.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001628280-26-054450. Derived: 6-month figure less the 3-month figure.Capital expenditure: $33.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001628280-26-054450. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$2.94bnGross margin not reported
Diluted EPS$3.92, FY2025
Free cash flow$588.8m, FY2025
Globus Medical Inc, key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m958Revenue, FY2021, twelve months to 2021-12-31$958.1m. XBRL concept us-gaap:Revenues. 10-K filed 2024-02-21, accession 0001562762-24-000032.Report this figure1,023Revenue, FY2022, twelve months to 2022-12-31$1.02bn. XBRL concept us-gaap:Revenues. 10-K filed 2025-02-20, accession 0001562762-25-000026.Report this figure1,568Revenue, FY2023, twelve months to 2023-12-31$1.57bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-24, accession 0001628280-26-011209.Report this figure2,519Revenue, FY2024, twelve months to 2024-12-31$2.52bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-24, accession 0001628280-26-011209.Report this figure2,939Revenue, FY2025, twelve months to 2025-12-31$2.94bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-24, accession 0001628280-26-011209.Report this figure
Gross margin%75.0%Gross margin, FY2021, twelve months to 2021-12-31. gross profit / revenueGross profit: $718.9m. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-02-21, accession 0001562762-24-000032.Revenue: $958.1m. XBRL concept us-gaap:Revenues. 10-K filed 2024-02-21, accession 0001562762-24-000032.Report this figure74.2%Gross margin, FY2022, twelve months to 2022-12-31. gross profit / revenueGross profit: $759.1m. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-02-21, accession 0001562762-24-000032.Revenue: $1.02bn. XBRL concept us-gaap:Revenues. 10-K filed 2025-02-20, accession 0001562762-25-000026.Report this figure65.1%Gross margin, FY2023, twelve months to 2023-12-31. gross profit / revenueGross profit: $1.02bn. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-02-21, accession 0001562762-24-000032.Revenue: $1.57bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-24, accession 0001628280-26-011209.Report this figurenot reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%17.9%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $172.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-21, accession 0001562762-24-000032.Revenue: $958.1m. XBRL concept us-gaap:Revenues. 10-K filed 2024-02-21, accession 0001562762-24-000032.Report this figure22.3%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $228.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-20, accession 0001562762-25-000026.Revenue: $1.02bn. XBRL concept us-gaap:Revenues. 10-K filed 2025-02-20, accession 0001562762-25-000026.Report this figure8.5%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: $133.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0001628280-26-011209.Revenue: $1.57bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-24, accession 0001628280-26-011209.Report this figure6.6%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $166.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0001628280-26-011209.Revenue: $2.52bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-24, accession 0001628280-26-011209.Report this figure16.3%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $479.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0001628280-26-011209.Revenue: $2.94bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-24, accession 0001628280-26-011209.Report this figure
Net margin%15.6%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $149.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-21, accession 0001562762-24-000032.Revenue: $958.1m. XBRL concept us-gaap:Revenues. 10-K filed 2024-02-21, accession 0001562762-24-000032.Report this figure18.6%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $190.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-20, accession 0001562762-25-000026.Revenue: $1.02bn. XBRL concept us-gaap:Revenues. 10-K filed 2025-02-20, accession 0001562762-25-000026.Report this figure7.8%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: $122.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0001628280-26-011209.Revenue: $1.57bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-24, accession 0001628280-26-011209.Report this figure4.1%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $103.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0001628280-26-011209.Revenue: $2.52bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-24, accession 0001628280-26-011209.Report this figure18.3%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $537.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0001628280-26-011209.Revenue: $2.94bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-24, accession 0001628280-26-011209.Report this figure
Diluted EPS$ per share1.44Diluted EPS, FY2021, twelve months to 2021-12-31$1.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-21, accession 0001562762-24-000032.Report this figure1.85Diluted EPS, FY2022, twelve months to 2022-12-31$1.85 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-20, accession 0001562762-25-000026.Report this figure1.07Diluted EPS, FY2023, twelve months to 2023-12-31$1.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-24, accession 0001628280-26-011209.Report this figure0.75Diluted EPS, FY2024, twelve months to 2024-12-31$0.75 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-24, accession 0001628280-26-011209.Report this figure3.92Diluted EPS, FY2025, twelve months to 2025-12-31$3.92 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-24, accession 0001628280-26-011209.Report this figure
Free cash flow$m219Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $276.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-21, accession 0001562762-24-000032.Capital expenditure: $56.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-21, accession 0001562762-24-000032.Report this figure104Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $178.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-20, accession 0001562762-25-000026.Capital expenditure: $74.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-20, accession 0001562762-25-000026.Report this figure165Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $243.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-24, accession 0001628280-26-011209.Capital expenditure: $78.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-24, accession 0001628280-26-011209.Report this figure405Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $520.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-24, accession 0001628280-26-011209.Capital expenditure: $115.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-24, accession 0001628280-26-011209.Report this figure589Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $753.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-24, accession 0001628280-26-011209.Capital expenditure: $164.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-24, accession 0001628280-26-011209.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Globus Medical Inc
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$853.8m10,806,724Added+309,310
JANUS HENDERSON GROUP PLC2026-03-31$656.8m7,623,095Not compared
Jupiter Topco LLC2026-06-30$647.9m8,200,423Not compared
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$403.5m5,107,532Added+74,800
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$394.6m4,994,385Added+114,926
Invesco Ltd.2026-06-30$340.5m4,309,771Reduced−6,883
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC2026-06-30$338.1m4,279,730New+4,279,730
STATE STREET CORP2026-06-30$293.5m3,714,029Added+123,657
Sculptor Capital LP2026-06-30$237.0m3,000,000Reduced−58,000
JPMORGAN CHASE & CO2026-06-30$230.8m2,743,850Added+148,542

Recent filings

All 753 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Globus Medical Inc, recent filings
FiledFormWhat it isAccession number
2026-08-0617:06 ET10-QQuarterly reportPeriod 2026-06-300001628280-26-054450
2026-08-0616:19 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001628280-26-054353
2026-06-0416:11 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001628280-26-040784
2026-05-0717:03 ET10-QQuarterly reportPeriod 2026-03-310001628280-26-032290
2026-05-0716:20 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001628280-26-032164
2026-04-2416:04 ETDEF 14AProxy statementPeriod 2026-06-030001628280-26-027196
2026-03-2317:26 ET8-K5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001628280-26-020612
2026-02-2417:08 ET10-KAnnual reportPeriod 2025-12-310001628280-26-011209
2026-02-2416:23 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001628280-26-011124
2026-01-0716:32 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001628280-26-001189

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 24, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1237831
Tickers
GMED
Exchange
NYSE
SIC code
3841 Surgical & Medical Instruments & Apparatus
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 11:47 ET. Listed shows no prices and gives no investment advice.